Back to top

Insulet raises FY26 adjusted EPS growth view to at least 30% from at least 25%

Cuts FY26 Drug Delivery Total Growth to 20%-22% from 21%-23% Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Insulet Corporation (PODD)